Flightglobal

Cavorite eVTOL developer Horizon obtains funding injection

Canadian eVTOL developer Horizon Aircraft has obtained an $8.4 million funding injection from a strategic investor. The company is working on a hybrid eVTOL designated the Cavorite X7, which will use ...
Business Wire

Horizon Therapeutics plc Initiates MIRROR Randomized Controlled Trial Evaluating KRYSTEXXA® (pegloticase injection) in Combination with Methotrexate to Increase Response Rates ...

DUBLIN-- (BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the initiation of a clinical trial evaluating KRYSTEXXA® (pegloticase injection) in combination with methotrexate as a ...
Business Wire

Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout

Horizon Pharma plc Initiates Clinical Trial to Evaluate KRYSTEXXA® (pegloticase injection) with Methotrexate to Enhance Response Rates for People Living with Uncontrolled Gout September 27, 2018 08:00 ...
Nasdaq

Horizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat ...

-- The AGILE trial is designed based on patient and clinician input and part of Horizon’s continued investment to impact the KRYSTEXXA patient experience -- DUBLIN--(BUSINESS WIRE)-- Horizon ...
Nasdaq

Horizon Therapeutics plc Announces FDA Has Granted Priority Review of the Supplemental Biologics License Application (sBLA) for the Concomitant Use of KRYSTEXXA® (pegloticase ...

-- sBLA seeks to expand the label to include KRYSTEXXA plus methotrexate to help more patients achieve a complete and durable response to therapy -- -- Application based on recent MIRROR randomized ...